PHARMACY

Health Mart ‘Resolves to Evolve’ in latest Town Hall CE series

BY Michael Johnsen

SAN FRANCISCO – In an effort to help independent pharmacies level the playing field so they can compete and grow their businesses, Health Mart announced Monday the kick off to its fourth Town Hall CE series with events Birmingham, Ala., and Oak Park, Ill.

“Health Mart is committed to delivering the insights and resources that help our pharmacists stay up to date on the market dynamics impacting independent pharmacy,” stated Crystal Lennartz, chief pharmacist, Health Mart. “The last few Town Hall series focused on understanding quality measures and implementing med sync to improve patient care and streamline their operations. Now, it’s about committing to action with a focus on improving their clinical, operational, and financial performance for the health of their business and their patients.”

The new “Resolve To Evolve: Maintaining Profitability and Advancing Care in a Changing Pharmacy World” events will help pharmacies increase efficiency, profitability and improve patient health outcomes that capture payer dollars.

Featuring 18 highly successful Health Mart owners, the Resolve to Evolve workshops will help attendees recognize how a planned and measurable approach is key to evolving their business model to maintain profitability. In the interactive peer-to-peer sessions, attendees will exchange valuable strategies about med sync, change management, and more with peers. Based on their goals, they will develop action steps to implement back in their pharmacy and learn how to motivate change with their staff.

All independent pharmacy owners, pharmacists and techs are invited.

All told, Health Mart will host nearly 90 events across the country through early 2017.  Over the past four years, Health Mart has hosted more than 300 peer-to-peer Town Hall meetings to help members understand the market dynamics impacting independent pharmacy.

In addition to this latest Town Hall series, Health Mart has invested heavily in helping pharmacies to stay ahead of the curve as the industry continues to go through rapid change with the Health Mart Pathway to Better Pharmacy Performance and Profit. Launched at McKesson ideaShare 2016, the Health Mart Pathway offers a strategic road map to help independent pharmacies shift the way they approach their clinical and financial performance and pharmacy operations. Detailing a pharmacist approved, realistic process for members to make practical changes to their business to enhance their profitability, the Health Mart Pathway also recommends the resources, tools and expert advice pharmacies need to build a successful future.

myHealthMart, which launched in conjunction with the Health Mart Pathway, is an online portal that enables pharmacies to proactively manage their business by providing access to personalized, up-to-date data, programs and insights for their pharmacy. The online tool provides a complete picture of their pharmacy’s clinical and business performance and one-stop access to Health Mart programs and resources. Personalized reports and dashboards enable pharmacies to see how their decisions are impacting their business, and setting custom goals helps track their progress towards business growth and performance targets. myHealthMart provides centralized, one-click access to educational, clinical and marketing resources and allows customers to explore new opportunities for their pharmacies in the program store. In addition, real-time notifications keep customers up to date on the information they need to know to deliver better patient outcomes and strengthen their competitive position.

“We understand that the changes asked by this evolving industry can often be difficult, and we want to help by providing independents with opportunities to share ideas with peers, and with information and resources that will help them implement change in their pharmacies and with their staff," noted Steve Courtman, president Health Mart. "Ultimately, the foundation of Health Mart’s strategy is to help our members perform their best clinically and implement innovative practices that ensure the viability and prosperity of their business for years to come.”

Health Mart is the largest independent pharmacy network with more than 4,700 locally owned community pharmacies across all 50 states.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Janssen’s Stelara to treat Crohn’s disease

BY David Salazar
SILVER SPRING, Md. — Janssen Biotech announced Monday that the Food and Drug Administration had approved its Stelara (ustekinumab) to treat moderately to severely active Crohn’s disease.  
 
It is now indicated for adults with Crohn’s disease who have failed or were intolerant to corticosteroid or immunomodulator treatments, but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant of one or more TNF blocker treatment. 
 
“Crohn's disease is a complex condition to treat, and not all therapies work for every patient,” study investigator and chief of gastroenterology at UC San Diego School of Medicine Dr. William J. Sandborn said. “The FDA approval of Stelara represents an important advancement in treating patients with Crohn's disease, as this therapy offers an alternate mechanism of action to induce and maintain clinical remission over time. Based on the results of the clinical development program, Stelara has the potential to benefit many adults living with Crohn's disease.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Humira biosimilar Amjevita from Amgen

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration has approved Amgen’s Amjevita (adalimumab-atto), a biosimilar of AbbVie’s Amgen (adalimumab) and the fourth U.S. biosimilar, the company announced Friday. The drug — Amgen’s first biosimilar — is indicated to treat seven inflammatory conditions, among them moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and moderate to severe chronic plaque psoriasis. 
 
"Approval of Amjevita is an exciting accomplishment as it marks a new chapter in Amgen's story of being a leader in biotechnology,” Amgen’s EVP research and development Dr. Sean Harper said. “In addition, Amjevita holds the potential to offer patients with chronic inflammatory diseases an additional treatment option.”
 
Like Humira, Amjevita contains a boxed warning about increased risk of serious infections leading to hospitalization or death, the FDA said. It also notes that lymphoma and other malignancies, some of them fatal, have been reported in children and adolescent patients treated with adalimumab products. 
 
“This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions,” FDA Center for Drug Evaluation and Research director Dr. Janet Woodcock said. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?